Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar;10(5):262. doi: 10.21037/atm-22-407

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2022 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Different survival prognosis of CAF subtypes. (A) Actual (left) and predicted (right) cellular composition of 24 pancreatic cancer samples deconvoluted by scRNA-seq and an SVR-based algorithm. (B) Pearson correlation of predicted and actual fibroblast composition in 24 pancreatic cancers. (C) Kaplan-Meier curves showing the survival difference between inflammatory CAF (upper), myofibroblastic CAF (middle) and antigen-presenting CAF (lower) high or low subgroups in a TCGA-PDAC cohort. (D) Images of multiplex immunohistochemistry of PDGFRα+/CXCL12+ inflammatory CAF and S100A4+/α-SMA+ myofibroblastic CAF (left), high iCAF enrichment (upper) and high myCAF enrichment (lower) in PDAC co-hort. Scale bars indicating 50 µm and 200 µm in lefthand/righthand panels (×20) and middle panel (×5). (E) Kaplan-Meier curves showing the survival difference between inflammatory CAF (left), and myofibroblastic CAF (right) high or low subgroup in the external validation cohort. CAF, cancer-associated fibroblast; PDAC, pancreatic ductal adenocarcinoma; iCAF, inflammatory cancer-associated fibroblast; myCAF, myofibroblast cancer-associated fibroblast.